Accendra Health Inc. (NYSE: ACH) has chosen to forego the establishment of an at-the-market equity issuance program given current market conditions. This program was envisioned to allow the company to raise modest amounts of equity to alleviate outstanding debt, particularly that trading below par …
Coherus Oncology, Inc. (NASDAQ: CHRS) has successfully secured a senior secured term loan facility amounting to $55 million, with a maturity date set for August 2031. This strategic financial maneuver aims to provide greater flexibility and extends the company's debt obligations, ensuring that they …
GE HealthCare Technologies Inc. (NASDAQ: GEHC) is set to welcome William Grogan as its new Chief Financial Officer on September 14, 2026. Grogan succeeds George Newcomb, who has been serving in the interim capacity and will revert to his prior role as Controller and …
Longevity Health Holdings, Inc. has announced a key settlement resolving its litigation with Puritan Partners LLC, which has been ongoing since November 2023. The settlement agreement entails exchanging existing claims for new 10% senior secured convertible notes valued at an aggregate principal amount of …
Positron Corp (OTC: POSC) has successfully established a line of credit that allows the company access to up to $2 million, a significant move intended to bolster its financial flexibility. This strategic financial maneuver is designed to support the company’s operational and growth initiatives.
Revenue Growth Driven by Increased Patient Volumes
Costco’s Strategic Entry into Medicare
Intelligent Bio Solutions Inc. (NASDAQ: INBS) reported its financial results for the fiscal year ending June 30, 2026, achieving total revenue of $4.2 million. This figure represents a strong 38% increase compared to the previous year’s revenue of approximately $3.05 million. The surge in …
AbbVie Inc. (NYSE: ABBV) has successfully completed a $500 million public offering of senior notes to enhance its financing capabilities for the acquisition of Apogee Therapeutics, Inc. The offering includes various classes of notes, featuring both floating and fixed interest rates, reflecting AbbVie's strategic …
Each holder of Coherus Oncology, Inc. (NASDAQ: CHRS)'s common stock,Par Value$0.0001, will receive one CVR for every share they own as of the record date. This move is aimed at offering stockholders a potentialRevenuestream linked to the future performance of the company’s remaining biosimilar …